For the quarter ending 2025-09-30, RYTM made $51,298,000 in revenue. -$54,279,000 in net income. Net profit margin of -105.81%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenues | 51,298,000 | 48,502,000 | 32,704,000 | 33,898,500 |
| Cost of sales | 5,499,000 | 5,543,000 | 3,648,000 | 3,296,500 |
| Research and development | 46,027,000 | 42,308,000 | 36,973,000 | 84,916,000 |
| Selling, general, and administrative | 52,425,000 | 45,947,000 | 39,087,000 | 36,256,000 |
| Total costs and expenses | 103,951,000 | 93,798,000 | 79,708,000 | 124,468,500 |
| Loss from operations | -52,653,000 | -45,296,000 | -47,004,000 | -90,570,000 |
| Other income (expense), net | 274,000 | 1,576,000 | -644,000 | 424,500 |
| Gain on settlement of forward contract | - | - | - | 0 |
| Interest expense | 4,742,000 | 5,817,000 | 5,409,000 | 5,379,000 |
| Interest income | 4,328,000 | 3,242,000 | 3,639,000 | 3,280,000 |
| Total other (expense), net | -140,000 | -999,000 | -2,414,000 | -1,674,500 |
| Loss before income taxes | -52,793,000 | -46,295,000 | -49,418,000 | -92,244,500 |
| Provision for income taxes | 111,000 | 337,000 | 80,000 | 105,500 |
| Net loss | -52,904,000 | -46,632,000 | -49,498,000 | -92,350,000 |
| Accrued dividends on convertible preferred stock | 1,375,000 | 1,349,000 | 1,322,000 | 669,500 |
| Net loss attributable to common stockholders | -54,279,000 | -47,981,000 | -50,820,000 | -93,019,500 |
| Earnings per share, basic | -0.82 | -0.75 | -0.81 | -1.53 |
| Earnings per share, diluted | -0.82 | -0.75 | -0.81 | -1.53 |
| Weighted average number of shares outstanding, basic | 66,261,055 | 63,684,359 | 63,059,165 | -30,618,269 |
| Weighted average number of shares outstanding, diluted | 66,261,055 | 63,684,359 | 63,059,165 | -30,618,269 |
RHYTHM PHARMACEUTICALS, INC. (RYTM)
RHYTHM PHARMACEUTICALS, INC. (RYTM)